Lu177 is better than cabazitaxel in patients with metastatic castration-resistant prostate cancer.
An unblinded, randomized phase 2 trial at 11 centers in Australia.
the researchers recruited men with metastatic castration-resistant prostate cancer for whom cabazitaxel was considered the next appropriate standard treatment.
Read more about >>
